Publisher
Springer Science and Business Media LLC
Reference28 articles.
1. Conroy T, Hammel P, Hebbar M, et al. Unicancer GI PRODIGE 24/CCTG PA.6 trial: A multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas. J Clin Oncol. 2018;36(18 Suppl):LBA4001.
2. Neoptolemos J, Palmer D, Ghana P. ESPAC-4: a multicenter, international, open-label randomized controlled phase III trial of adjuvant domination chemotherapy of gemictaibine (GEM) and capecitabine (CAP) versus mono therapy gemicitabine in patients with resected pancreatic ductal adenocarcinoma—five year follow-up. J Clin Oncol. 2020;38:15.
3. Oettle H, Neuhous P, Hochhause A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer. AMA. 2013;310(14):1473–81.
4. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Pancreatic Adenocarcinoma. Version 1.2020. National Comprehensive Cancer Network® (NCCN®). www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf (log-in required). Accessed 20 Feb 2022.
5. Cameron JL, He J. Two thousand consecutive pancreaticoduodenectomies. J Am Coll Surg. 2015;220:530–6.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献